XXII ASSEMBLEA MaNGO MILANO

STANDARD TREATMENTS AND NEW DIRECTIONS IN GYNAECOLOGICAL CANCERS

MILANO June 26th-29th, 2025

Responsabili Scientifici:
NICOLETTA COLOMBO, FRANCESCO RASPAGLIESI

MaNGO

SESSION 2 - ENDOMETRIAL CANCER STUDIES

Chairs: Elena Biagioli, Elisa Piovano, Giulia Tasca

Opening studies in EC at relapse (MaNGO-ENGOT)

S. Cosio, Pisa

ENDOMETRIAL CANCER TRIALS - relapse

Opening and recruiting trials

- REALITY (YMaGiNe)
- ENGOT-en26 / Ascent-gyn-01

Opening and planned trials

- ENGOT-en25 / BNT323-01
- ENGOT-en28 / BLUESTAR
- ENGOT-en31 / RAINFOL-03

PFS LEN + PEMBRO in Advanced EC. Study 309-KEYNOTE-775 OS





- ✓ On April 2, 2022: law n. 648/1996 for PEMBRO + LENV for pts with pMMR tumor.
- ✓ On July 18, 2023 the full reimbursement approval PEMBRO + LENV was granted in Italy, for patients with advanced EC pretreated with platinum-based chemotherapy, including both dMMR and pMMR patients.

Endometrial cancer trials Relapse - Opening & recruiting REALITY

REALITY: REal-world activity and sAfety of pembroLizumab-lenvatInib combination in patients with advanced endomeTrial cancer in ItalY

MaNGO – MITO Retrospective/prospective, multicenter, observational study aimed to evaluate clinical outcomes and safety of patients with advanced endometrial cancer treated with pembrolizumab-lenvatinib combination in a real-world setting

- Sponsor: Istituto di Ricerche Farmacologiche Mario Negri – YMaGiNe
- PI MaNGO: Monika Ducceschi ; PI MITO: Claudio Zamagni

Many objectives:

- ✓ To evaluate the efficacy of pembrolizumab-lenvatinib combination in terms of progression-free survival (PFS)
- ✓ To evaluate the safety profile of the combination as measured by the rate of dose reductions/interruptions.

Endometrial cancer trials Relapse - Opening & recruiting REALITY

Group	Hospital	Principal Investigator	Activated	Patients included
MaNGO	Fondazione IRCCS - Istituto Nazionale Tumori, Milano	Monika Ducceschi	Yes	23
MaNGO	Ospedale Sant'Anna, Torino	Fulvio Borella	Agreement under revision	-
MaNGO	Ospedale Manzoni, Lecco	Federica Villa	Yes	4
MaNGO	Istituto Europeo di Oncologia, Milano	Mariateresa Lapresa	Yes	0
MaNGO	Ospedale San Gerardo, Monza	Stefania Canova	Yes	5
MaNGO	Istituto Oncologico Veneto, Padova	Giulia Tasca	Yes	0
MaNGO	Arcispedale S. Maria Nuova, Reggio Emilia	Alessandra Bologna	Issues with privacy	-
MaNGO	Ospedale Sant'Anna, Como	Rosalinda Coviello	Agreement under revision	-
MaNGO	Policlinico Careggi, Firenze	Maria Cristina Petrella	Issues with privacy	-
MaNGO	Ospedale Umberto I, Roma	Federica Tomao	In signatures	-
MaNGO	Università di Torino Ospedale Mauriziano Umberto I – Dip. Ginecologia Oncologica, Torino	Annamaria Ferrero	Yes	5
MaNGO	Azienda Ospedaliero-Universitaria di Parma	Angelica Sikokis	Agreement under revision	-
Total MaNGO patients				**37**
Total MITO patients				**64**

- **Sites active: 19**
- **Sites involved: 36**
- **Study approved by ethical committee on May 23rd 2024.**
- **An amendment is ongoing to expand the number of sites**

- **Abstract submission planned for ESGO 2026**

Collaboration is required to finalize site activation and to complete the RedCap Database

ENGOT-en26/Ascent-gyn-01 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy



IMMU-132-01: {Bardia 2021}.
Phase 1/2 basket study, enrolled 18 metastatic EC to receive SG 10 mg/kg on D 1, 8 q 21-day
ORR: 22.2% , mPFS: 3.2 months, mOS: 11.9 months

IMMU-132-11 (TROPiCS-03): Santin 2023}.
Phase 2 study enrolled 41 metastatic EC to receive SG 10 mg/kg on Days 1, 8 q21.
by INV: ORR: 22% , (PR: 9/41), DOR: 8.8 months, PFS: 4.8 months.
within the subgroup who received prior CT + anti-PD-1/PD-L1:
ORR: 20.0% (PR: 7 /35), mPFS: 4.2

ENGOT-en26/Ascent-gyn-01 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

- ENGOT Model C
- ENGOT PI: Nicoletta Colombo
- GOG led study
- ENGOT lead group: MaNGO
- Sponsor: Gilead Sciences

Key Eligibility Criteria

- Recurrent endometrial carcinoma
- Histologically confirmed diagnosis of epithelial endometrial carcinoma, including carcinosarcoma
- Prior treatment with platinum-based chemotherapy and anti-PD-(L)1 therapy.
- Measurable or non-measurable disease



Stratification Factors

- # of Prior lines of systemic therapy in any setting (£2 vs 3)
- Prior Anti-PD-(L)1 therapy (yes vs no)
  Enrollment of participants who have not received prior anti-PD-1/PD-L1 therapy will be capped at approximately 10%.
- Geographic region (North America/Europe vs Asia/ROW)

Key Study Endpoints

Primary Endpoint:
- PFS by BICR
- OS

Key Secondary Endpoints:
- ORR by BICR
- Change from baseline and TTdD in Physical Function as assessed by EORTC-QLQ-C30

Secondary Endpoints:
- PFS by INV
- ORR by INV
- DOR, CBR by BICR and INV
- Safety
- Change from baseline in GHS/QoL as assessed by EORTC-QLQ-C30

ENGOT Study Update at 20 June 2025

Study Metrics Global	
Site Activated / Site Activations Expected	173 / 194
Global Enrolment / Expected Enrolment	348 / 520
N of patients enrolled within ENGOT	102

Study Sites Planned: Approximately ~175 sites globally, Partnership with GOG-F, ENGOT, LACOG, APGOT

Last patient In: Q4 2025

ENGOT Group	# of sites planned	# of sites to be actived	# of sites activated	# Screened patients	# Randomized
MaNGO	7	0	7	17	13
GINECO	8	0	8	30	21
AGO	8	0	8	8	4
GTG-UK	6	1	5	6	5
CEEGOG	4	1	3	1	1
HeCOG	5	1	4	6	6
GEICO	11	0	11	24	18
ISGO	6	0	6	11	6
MITO	6	0	6	27	23
PGOG	5	2	3	7	6
TOTAL	**66**	**5**	**61**	**137**	**103**

MaNGO Study Update at 9 June 2025

Site Name	Site Status	PI Name	Site Activation Date	# Patient screened	# Patient enrolled
Istituto Europeo di Oncologia	Open	Nicoletta Colombo	23 Jan 2025	5	5
AOU Careggi	Open	Maria Cristina Petrella	20 Jan 2025	6	5
Oncologia Medica Ospedale Santa Chiara Università di Pisa	Open	Carmelo Bengala	18-Feb-2025	1	0
Fondazione IRCCS – Istituto Nazionale dei Tumori di Milano	Open	Monika Ducceschi	19-Jun-25	0	0
Istituto Oncologico Veneto IRCCS	Open	Valentina Guarneri	08-May-25	0	0
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino	Open	Elisa Piovano	09-May-25	2	1
Presidio Ospedaliero Alessandro Manzoni di Lecco	Open	Federica Villa	24-Feb-25	3	2

Endometrial cancer trials Relapse - Opening & planned ENGOT-en25 / BNT323-01

CONFIDENTIAL

Endometrial cancer trials Relapse - Opening & planned ENGOT-en28 / BLUESTAR

CONFIDENTIAL

Endometrial cancer trials Relapse - Opening & planned ENGOT-en31 / RAINFOL-03

CONFIDENTIAL


Grazie…..